ECRI is an independent, nonprofit organization improving the safety, quality, and cost effectiveness of care across all healthcare settings. The combination of evidence-based research, medical device testing, and knowledge of patient safety makes ECRI uniquely respected by healthcare leaders and agencies worldwide. For more than 50 years, ECRI has had an unwavering dedication to transparency and strict conflict-of-interest policies. The organization has earned a reputation as the trusted voice of unbiased, research-based assurance for tens of thousands of members around the world using its solutions to minimize risk and improve patient care. As a leading provider of spend and clinical data analytics and solutions, we provide comprehensive and unique market and competitive intelligence on a wide array of healthcare technologies. Our market intelligence includes transactional pricing, independent lab-based tested devices and equipment, safety alerts and history, evidence-based health technology assessments, and disruptive technologies on the horizon. ECRI has the only medical device testing labs in North America and the Asia Pacific where bio-engineers conduct hands-on independent device testing for safety and human factors usability. ECRI is designated an Evidence-based Practice Center by the U.S. Agency for Healthcare Research and Quality. ECRI and the Institute for Safe Medication Practices PSO is listed as a federally certified Patient Safety Organization by the U.S. Department of Health and Human Services.
External link for ECRI
5200 Butler Pike
Plymouth Meeting, Pennsylvania 19462, US
Sheikh Zayed Road, PO Box 71059
Dubai, dubai, AE
Taman Danau Desa
Kuala Lumpur, 58100, MY
Suite 104
Welwyn Garden City, Hertfordshire AL7 3BQ, GB
ECRI reposted this
SPECIAL ALERT: Manufacturer’s dexmedeTOMIDine premixed IV bags may be packaged within an overwrap labeled as acetaminophen! Please read the National Alert Network (NAN) warning with ISMP’s safe practice recommendations: https://hubs.la/Q02GghXK0 #medicationsafety #medsafety #patientsafety #medicationerrors #hospitals #pharmacist #nurses ECRI
NEW | Human Factors Engineering: Systems Thinking to Enhance Patient Safety A recent retrospective study in the New England Journal of Medicine reported that adverse events occur in nearly one in four hospital admissions. Meeting this patient safety challenge requires understanding and addressing healthcare as a complex, sociotechnical system. During this two-day live training, ECRI’s human factors engineers will provide the foundational knowledge to understand patient safety adverse events from a true systems perspective for effective and sustainable solutions. Register now: https://hubs.la/Q02FC3JG0 #patientsafety #safety #healthcaresafety #quality #riskmanagement #healthcare
[INNOVATION UPDATE] Bone marrow aspiration is a common medical procedure used to diagnose various hematologic malignancies. Following extraction from the patient, manual analysis is required by an expert to categorize and quantify different types of cells. Full-Field Bone Marrow Aspirate (FF-BMA) Application pairs a full-field imaging platform with artificial intelligence to automatically categorize and quantify cells. An expert reviewer can then assess preselected cells by approving or modifying the automated categorizations. This allows for remote assessment of samples and may improve turnaround time between testing and diagnosis. Learn more about this innovative technology in the Emerging Health Care Innovation Brief: https://hubs.la/Q02DBRNn0 #blooddisorders #hematology #artificialintelligence #patientcare #healthcare #innovation #horizonscanning #ecri
[INNOVATION UPDATE] WHIM Syndrome is named for its symptoms that include warts, hypogammaglobulinemia, infections, and myelokathexis (a disorder causing low levels of white blood cells). In patients with WHIM, an overactive receptor known as CXCR4 causes mature blood cells to be retained in the bone marrow preventing their participation in immune system functions. Mavorixafor (Xolremdi) is a small molecule inhibitor of CXCR4 that was recently approved by the US Food and Drug Administration to boost circulating white blood cells in patients with WHIM Syndrome. Learn more about this innovative treatment in the latest Emerging Health Care Innovation Brief: https://hubs.la/Q02DBNJs0 #whim #rarediseases #immunodeficiency #patientcare #healthcare #innovation #horizonscanning #ecri
[WATCH NOW] The idea that diagnosis is a single event that happens at a single point of time by a single healthcare provider is a common misconception—one that doesn’t account for the complex, multifaceted system of patients, family members, providers, and technologies. In this episode, Victor Lane Rose, Executive Director, of Aging and Ambulatory Care at ECRI, discusses diagnosis and describes why patient, family, and caregiver participation is especially important in diagnosing Alzheimer’s and other dementias. Watch now on YouTube: https://hubs.la/Q02FPqPJ0 #dementiacare #seniorcare
Save money and time safely by using SurgiSmartIQ. SurgiSmartIQ helps you pinpoint areas where you are overspending, secure better prices, find alternative suppliers, negotiate stronger contracts with vendors, and identify discrepancies between contract prices and actual price paid. Better negotiate with stakeholders and clinicians and make informed decisions with confidence. Chat with our experts today: https://hubs.la/Q02DyqwZ0
❗Imagine detecting diseases before patients even show symptoms—it may now be possible with breakthrough MRI technology❗ A new MRI #technology is revolutionizing how we detect diseases at their earliest stages. This cutting-edge method promises to identify #diseases like cancer much earlier than current techniques, potentially saving countless lives through timely intervention. Northeastern University's new QUTE-CE MRI technology transforms traditional #MRI machines, offering non-invasive, high-resolution imaging that could revolutionize #diagnostics. What are your thoughts on the impact of such advancements in #healthcare? Could this be the game-changer we've been waiting for⁉️ Share your insights below and let’s discuss how we can leverage these innovations to improve patient outcomes. 💬 Source: https://hubs.la/Q02FHQjB0. #HealthcareInnovation #EarlyDetection #MedicalBreakthroughs #FutureOfHealthcare #ECRI #NortheasternUniversity
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that causes loss of muscle control and mobility, eventually leading to paralysis. The life expectancy for individuals with ALS is two to five years from diagnosis. ECRI’s Horizon Scanning Analysts are exploring a range of emerging interventions for this disease and need the input of the ALS community. Are you interested in sharing your insights? Fill out a brief form and a member of our team will be in touch: https://hubs.la/Q02DBPCy0 #amyotrophiclateralsclerosis #als #neurology #rarediseases #advocacy #innovation #patientcare #horizonscanning
In the latest edition of TechNation, ECRI shared insights on “Incident Management and Investigation: Mastering the Process.” The cover story features ECRI’s 7-point approach to manage and investigate healthcare incidents from beginning to end. The IMI Plan includes (1) awareness, (2) response, (3) fact gathering, (4) analysis, (5) conclusions (6) recommendations, and (7) legal considerations. “Hospital errors are the third-leading cause of death in the United States. After an incident occurs, it becomes imperative that a comprehensive investigation is completed to prevent recurrence and limit risk to the organization. However, missteps and gaps in the process, or a lack of investigation experience and resources, can leave organizations open to recurrence and costly claims,” says Barbara Malanga, director, preventative solutions and device safety operations-device safety at ECRI.” Read the cover story for ECRI expertise: https://hubs.la/Q02DWMx10
The number of orthopedic procedures in outpatient settings like ASCs is growing, exceeding inpatient procedures by 33 times, according to the American Joint Replacement Registry's 2023 annual report. With the rapid shift from acute care to ASCs, how can you be sure that you are maximizing savings? SurgiSmartIQ is designed to deliver data-driven cost savings to orthopedics by helping you: • Understand total joint costs • Assess contract compliance • Reduce spend safely Start realizing savings now: https://hubs.la/Q02DygSw0 #orthopedics #asc #ambulatorysurgerycenters